Multiple predicted inflammatory and gout-related targets

The term "Multiple predicted inflammatory and gout-related targets" does not refer to a single molecular entity but rather a heterogeneous collection of proteins involved in the pathogenesis of gout and hyperuricemia. This group typically includes enzymes like xanthine oxidase (XO), which is the primary target for reducing uric acid production (Richette & Bardin, 2010, Lancet), and renal transporters such as URAT1 (SLC22A12) and ABCG2, which are critical for urate homeostasis (Dalbeth et al., 2021, Nature Reviews Disease Primers). Additionally, it encompasses key inflammatory mediators, most notably the NLRP3 inflammasome and Interleukin-1 beta (IL-1β), which drive the acute inflammatory response to monosodium urate crystals (Kingsbury et al., 2011, Joint Bone Spine). Because this designation aggregates multiple distinct biological targets with diverse structures and functions, it is considered a non-specific descriptor often used in network pharmacology to summarize the predicted polypharmacological effects of complex therapeutic interventions. Consequently, it is not a valid single therapeutic target for drug development but a conceptual grouping of various pathways relevant to gout management.

Other names

Gout-related targetsInflammatory targets in goutHyperuricemia-related proteins

Inhibition of xanthine oxidase to reduce uric acid production; inhibition of renal transporters (URAT1, ABCG2) to increase urate excretion; and antagonism of inflammatory mediators like IL-1β or the NLRP3 inflammasome to suppress crystal-induced inflammation.